Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer

Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.